>>NCT00265148
Inclusion criteria:.
- Is male or if female meets one or more of the following criteria:.
- Post-menopausal females defined as menopause is defined as>6months without menstrual period with an appropriate clinical profile, e.g. age appropriate, history of vasomotor symptoms. However if indicated this should be confirmed by oestradiol and FSH levels consistent with menopause (according to local laboratory ranges). Women who are on HRT treatment and have not been confirmed as post-menopausal should be advised to use contraception.(See Appendix 4)Pre-menopausal females with a documented (medical report verification) hysterectomy and/or bilateral oophorectomy only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
- Meets the National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for Alzheimer's disease, regardless of date of diagnosis relative to study entry date. (See Appendix 5) Has an Alzheimer's disease status of mild to moderate, as classified by a Mini Mental State Examination (MMSE) score of 16-26 inclusive at screening.
Is aged >/= 50 to </= 85 years Prior and current use of medication corresponds with criteria listed in Appendix 3.
- Has the ability to comply with requirements of cognitive and other testing.
- Has a permanent caregiver who is willing to attend all visits, oversee the subject's compliance with protocol-specified procedures and study medication and report on subject's status. (Subjects living alone or in a nursing home are not eligible).
- Has provided full written informed consent prior to the performance of any protocol-specified procedure; or if unable to provide informed consent due to cognitive status, provision of informed consent by cognitively intact legally acceptable representative (Where this is in accordance with local laws, regulations and ethics committee policy.) Caregiver has provided full written informed consent prior to the performance of any protocol-specified procedure.
Exclusion criteria:.
- Is unsuitable for MRI scanning as assessed by local pre-MRI questionnaire (GSK to review.).
- Has a history of or suffers from claustrophobia.
- Is unable to lie comfortably on a bed inside a PET camera with their head in the field of view for at least 60 minutes as assessed by physical examination and medical history (e.g. back pain, arthritis).
- Has a history or presence of other neurological or other medical conditions that may influence the outcome or analysis of the PET scan results. Examples of such conditions include but are not limited to stroke, traumatic brain injury, epilepsy or space occupying lesions.
- History of Type I or Type II diabetes mellitus.
- Fasting plasma glucose level>126mg/dL (>7.0mmol/L) or HbA1c>6.2%.
- History or clinical/laboratory evidence of moderate congestive heart failure defined by the New York Heart Association criteria (class I-IV)(See Appendix 6).
Ejection fraction</=40% determined by echocardiogram or any other abnormality on echocardiography which in the view of the investigator required further investigation or intervention or significant abnormalities on screening ECG (in accordance with the definitions below). Significant ECG abnormalities for the purposes of this study. Detection of any of the following abnormalities renders the subject ineligible for the study: 1. ECG heart rate <50 and >100 bpm 2. Any previously unrecognised sustained or paroxysmal arrhythmia requiring further intervention e.g. anticoagulation, cardioversion, anti-arrhythmic agent, further investigation etc. 3. PR interval >0.3 s, 2nd or 3rd degree heart block, symptomatic bifascicular block, trifascicular block. 4. Multifocal ventricular ectopy. 5. Ventricular bigemini or couplets, triplets etc. ECG abnormalities permitted at entry to this study. A subject will not be rendered ineligible by the presence of any of the following abnormalities: 1. AF with a heart rate <=90 in subjects receiving appropriate anti-platelet or anticoagulant therapy. 2. 1st degree heart block (PR<=0.3 s). 3. Subjects with a paced rhythm (further information required if subject has an implantable Cardiac Defibrillator). 4. Atrial ectopic beats. 5. Unifocal ventricular ectopic beats. 6. Left or right bundle branch block. 7. Asymptomatice bifascicular block. 8. Left ventricular hypertrophy. 9. Q waves present suggesting previous MI. 10. Repolarisation abnormalities History of new cardiovascular event within the last 6 months (i.e. intervention, percutaneous coronary intervention, vascular surgery, acute coronary syndrome [non Q-wave myocardial infarction, Q-wave myocardial infarction, unstable angina) or significant arrhythmia; or major intervention (e.g. cardiac surgery or angiography plus stenting) scheduled.
- History or clinical laboratory evidence of cerebrovascular disease (stroke, transient ischaemic attack, haemorrhage) or diagnosis of possible, probable or definite vascular dementia in accordance with National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN) criteria (See Appendix 8).
- History or evidence of any other CNS disorder that could be interpreted as a cause of dementia: e.g. structural abnormality, epilepsy, infectious or inflammatory/demyelinating CNS conditions, Parkinson's disease.
Significant peripheral oedema at the time of screening as assessed by Clinical Evaluation of Oedema and/or Signs of Congestive Heart Failure (Appendix 14).
- History of major psychiatric illness such as schizophrenia or bipolar affective disorder or current depression (score on Hospital Anxiety and Depression Scale (HADS) depression questions >7, See Appendix 9).
Systolic blood pressure >165 mmHg or diastolic blood pressure >95 mmHG whilst receiving optimal antihypertensive therapy according to local practice.
Clinically significant anaemia (i.e.haemoglobin <11g/dL for males or <10 g/dL for females) or presence of haemoglobinopathies which would prevent accurate assessment of HbA1c.
Renal dysfunction, defined as creatinine clearance <30 ml/min (calculated from serum creatinine using the Cockcroft-Gault formula, See Appendix 10).
ALT, AST, total bilirubin or alkaline phosphatase >2.5 times the upper limit of normal laboratory range or history of severe hepatobiliary disease (e.g. hepatitis B or C or cirrhosis (Childs-Pugh classes B/C) without enzyme elevation.
- Fasting triglycerides >12mmol/L Abnormal/positive result within the past 12 months or at screening for any of the following tests: vitamin B12 (</=200pg/mL), syphilis serology, thyroid stimulating hormone.
- History or presence of gastro-intestinal, hepatic or renal disease or other condition known to interfere with absorption, distribution, metabolism or excretion of drugs.
any clinically relevant abnormality, medical or psychiatric condition, which, in the opinion of the investigator, makes the subject unsuitable for inclusion in the study.
- Has donated >/= ml of blood within the past 2 months. Use of any other investigational agent within 30 days or 5 half-lives (whichever is longer) prior to the screening visit.
History of alcohol abuse or of drug abuse within the past 6 months (or has tested positive for drugs of abuse at screening).
Subject is unable (with assistance, if appropriate) to take study medication as prescribed throughout the study.
- History of non-compliance with prescribed medication or risk of non-compliance with study medication or procedures.
Subject is an immediate family member or employee of the participating investigator or of any of the participating site staff.
Shows any neurological abnormality by MRI, which in the opinion of the Principal Investigator would introduce additional risk factors, study procedures or effect endpoint data. MRI scanning will only be conducted on subjects who satisfy all other eligibility criteria.
- History of bone marrow transplant Exhibits screening/baseline results not consistent with AD e.g. radiological findings or results on cognitive tests.
Use of tacrine within 30 days prior to the screening visit.

>>NCT01238458
Inclusion Criteria:.
- Both genders >= 50 years old.
- Written and dated informed consent by self or by legal representative, to be obtained before any of the study procedures.
- 30 cognitively normal volunteers with no evidence of significant cognitive impairment by history and psychometrictesting (MMSE > 24).
- 60 subjects with a diagnosis of AD according to the NINCDS-ADRDA criteria.
- 60 subjects with a diagnosis of MCI.
Exclusion Criteria:.
1. Pregnant or becoming pregnant during the study (as documented by pregnancy testing at screening or at any date during the study according to the PI discretion) or current breast feeding.
2. Modified Hachinski ischemic score of >4 or those who meet the NINDS-AIREN criteria for vascular dementia.
3. Any subject who has a clinically significant abnormal laboratory values, and/or clinically significant or unstable medical or psychiatric illness.
- Clinically significant hepatic, renal, pulmonary, metabolic or endocrine disturbances, especially thyroid disease;.
- Current clinically significant cardiovascular disease. Clinically significant cardiovascular disease usually includes one or more of the following:.
- cardiac surgery or myocardial infarction within the last 6 months;.
- unstable angina.
- coronary artery disease that required a change in medication within the last 3 months.
- decompensated congestive heart failure.
- significant cardiac arrhythmia or conduction disturbance, particularly those resulting in atrial or ventricular fibrillation or causing syncope, near syncope or other alterations in mental status.
- severe mitral or aortic valvular disease.
- uncontrolled high blood pressure.
- congenital heart disease.
- clinically significant abnormal result on ECG, including but not limited to QTc>450 msec iii. Clinically significant infectious disease, including AIDS or HIV infection or active hepatitis B, active hepatitis C, HIV-1 or HIV-2.
4. History of drug or alcohol abuse within the last year or prior prolonged history of abuse.
5. Patients who have the evidence of neurodegenerative disorders other than AD, cognitive impairment resulting from trauma or brain damage, brain infarction, clinically significant psychiatric disease, epilepsy, are excluded.

>>NCT01574456
Inclusion Criteria:.
Patients with AD:.
- Informed consent before participation in the study.
- Received standard diagnostic procedure according to the Parelsnoer Initiative procedure.
- Diagnosed with dementia of the Alzheimer's type.
- Clinical dementia rating (CDR) of 1, which means a mild to moderate stage of dementia.
- MMSE >= 20 and patients are mentally competent (in general, individuals with an MMSE >= 18 are considered mentally competent).
Patients with prodromal AD:.
- Informed consent before participation in the study.
- Received standard diagnostic procedure according to the Parelsnoer Initiative procedure.
- Diagnosis of prodromal dementia according to the Dubois criteria (16).
- CDR of 0.5, which suggests a very mild stage of dementia.
- Memory impairment defined as Delayed Recall on Verbal Learning Test (15 WLT) < 1.5 SD.
- MMSE >= 20 and patients are mentally competent.
- Medial temporal lobe atrophy scale MTA >= 1 (17) OR abnormal levels of A42, t-tau or p-tau.
Healthy participants:.
- Informed consent before participation in the study.
- No Diagnosis of dementia, prodromal dementia or mild cognitive impairment.
- MMSE >= 26.
- No substantial memory complaints (according to participant).
- Age, gender and education is matched to the patient groups.
Exclusion Criteria:.
- Contraindications for scanning (e.g. brain surgery, cardiac pacemaker, metal implants, claustrophobia, large body tattoos).
- Contraindications for contrast agent Gadovist (renal failure) as determined by the estimated Glomular Filtration Rate eGFR < 30 mL/min.
- Major vascular disorders (e.g. stroke, heart disease).
- Psychiatric or neurological disorders: Major depression (< 12 months); history of schizophrenia; bipolar disorder; psychotic disorder NOS or treatment for a psychotic disorder (< 12 mnd); cognitive impairment due to alcohol abuse; epilepsy; Parkinson's disease; MS; brain surgery; brain trauma; electroshock therapy; kidney dialysis; Meniere's disease; and brain infections.
- Structural abnormalities of the brain.
- Cognitive impairment due to alcohol/drug abuse.
- Absence of reliable informant (for patient groups).

>>NCT02017340
Inclusion Criteria:.
1. Age range: Adult subjects, males and females over age 50 years.
2. Prior diagnosis of mild to moderate probable AD based on NINCDS-ADRDA criteria (see Appendix B) and.
3. Standardised Mini-Mental State Examination (SMMSE) score > 12 on stable dose (>3 months of cholinesterase inhibitor and or memantine). Subjects who are not on cholinesterase inhibitors or memantine due to poor tolerability and/or who will not require treatment with these medications during the course of the study can be included.
4. Collateral informants such as a spouse, family member, close friend. The informant must have close contact with the subject and agree to monitor/manage study drug adherence, observe for possible adverse events, assist with psychometric measures requiring informant information and accompany the subject to all evaluation visits.
5. Fluency in relevant language sufficient to reliably complete all study assessments.
6. Systolic BP > 100 mmHg but <= 159 mmHg and diastolic BP > 65 mmHg but <= 99 mmHg on resting office based BP measurements or a Systolic BP > 105 mmHg but <= 140 mmHg and diastolic BP > 70 mmHg but <= 90 mmHg on ABPM measurement.
Exclusion Criteria:.
1. Subjects with co-morbid dementia due to other neurological disorders such as Parkinson's disease, vascular dementia, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma or multiple sclerosis, as well as subjects with HIV disease, neurosyphilis, history of significant head trauma with loss of consciousness followed by persistent neurological deficits, known structural brain abnormalities or any other condition known to interfere with cognitive function.
2. Subjects currently taking any calcium channel blocker or Beta-blocker.
3. Subjects who in the opinion of the investigator, have a medical condition that would preclude them from participating in the study (e.g.hemodynamically significant coronary artery disease., chronic heart failure, syncope within the past year, significant valvular heart disease i.e. severe aortic and mitral stenosis.. symptomatic orthostatic hypotension within the last year, subjects requiring more than one agent to control BP.) or subjects who in the opinion of the investigator are unlikely to complete per protocol due to care issues etc:.
4. Current Axis I diagnosis of schizophrenia, bipolar disorder, major depression. Subjects who are currently or who have within the past year met criteria for drug or alcohol abuse or dependence.
5. Pregnant women or women who may possibly become pregnant.
6. Subjects with a history of hypersensitivity to nilvadipine (Nivadil).
7. Subjects who have taken an investigational or other unapproved drug during the 30 days or five half-lives, whichever is longer, prior to baseline.
8. Subjects who are participating in other research studies.
9. Patients with a SBP of <= 100 mmHg and/or a DBP of <= 65 mmHg on office based BP measurements or a SBP <= 105 mmHg and/or a DBP of <= 70 mmHg on ABPM will not be included in the study.

>>NCT00369603
Inclusion Criteria:.
- Must meet diagnosis of mild Alzheimer's disease.
- Must have a family member or caregiver who is willing to attend all study visits and provide information on your participation in the study.
- If female, must be post-menopausal.
- Must be able to swallow tablets.
Exclusion Criteria:.
- Metal implants or medical devises unsafe for MRI use.
- Pre-menopausal female.
- HIstory of recent head injury.
- Significant major, life-threatening illness or injury (e.g., stroke, AIDS, etc.).
- Vascular dementia or any dementia other than Alzheimer's Disease.
- History of significant alcoholism or drug abuse.
- History of seizure disorder, developmental delay or major psychiatric illness.

>>NCT01565343
Inclusion Criteria (AD group):.
- Greater than 50 years of age.
- Probable AD according to the National Institute of Neurological and Communication Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria.
- Mild/moderate dementia as evidenced by a Mini-Mental State Examination (MMSE) score ranging from 10 to 24, boundaries included, at screening.
- History of cognitive decline gradual in onset and progressive over a period of at least 6 months.
Inclusion Criteria (healthy volunteer group):.
- 35 to 55 years of age, inclusive.
- MMSE of 29 or greater.
Exclusion Criteria (both groups):.
- Neurodegenerative disorders other than AD, including but not limited to Parkinson's disease, Pick's disease, fronto-temporal dementia, Huntington's chorea, Down syndrome, Creutzfeldt-Jacob disease, normal pressure hydrocephalus and progressive supranuclear palsy.
- Diagnosis of other dementing / neurodegenerative disease.
- Diagnosis of mixed dementia.
- Cognitive impairment resulting from trauma, hypoxic damage, vitamin deficiency, brain infection, brain cancer, endocrine disease or mental retardation.
- Clinically significant infarct or possible multi-infarct dementia as defined by the NINCDS criteria.
- Evidence on screening MRI or other biomarker that suggests alternate etiology for cognitive deficit (for healthy controls, evidence suggesting the presence of AD pathology).
- Clinically significant psychiatric disease.
- History of epilepsy or convulsions.
- Clinically significant hepatic, renal, pulmonary, metabolic or endocrine disturbances.
- Current clinically significant cardiovascular disease.
- Received investigational medication within the last 30 days.

>>NCT00898807
Inclusion criteria.
- Probable Alzheimer's disease (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association criteria), with Mini-Mental score of 5-28 inclusive.
- A medication for agitation is appropriate, in the opinion of the study physician.
- Clinically significant agitation for which either.
1. the frequency of agitation as assessed by the Neuropsychiatric Inventory (NPI) is 'Very frequently', or.
2. the frequency of agitation as assessed by the NPI is 'Frequently' AND the severity of the agitation as assessed by the NPI is 'Moderate' or 'Marked'.
- Provision of informed consent for participation in the study by patient or surrogate (if necessary) and caregiver.
- Availability of primary caregiver, who spends several hours a week with the patient and supervises his/her care, to accompany the patient to study visits and to participate in the study.
- No change to Alzheimer's disease (AD) medications within the month preceding randomization, including starting, stopping or dosage modifications.
Exclusion criteria.
- Meets criteria for Major Depressive Episode by Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV (TR) criteria.
- Presence of a brain disease that might otherwise explain the presence of dementia, such as extensive brain vascular disease, Parkinson's disease, dementia with Lewy bodies, traumatic brain injury or multiple sclerosis.
- Psychosis (delusions or hallucinations) requiring antipsychotic treatment in the opinion of the study physician.
- Prolonged measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle (QT interval).
- Treatment with citalopram is contraindicated in the opinion of the study physician.
- Failure of past treatment with citalopram for agitation after adequate trial at a minimally accepted dose (greater than or equal to 20 mg/day).
- Treatment with a medication that would prohibit the safe concurrent use of citalopram, such as Monoamine oxidases (MAO) inhibitors.
- Need for psychiatric hospitalization or suicidal.
- Current participation in a clinical trial or in any study that may add a significant burden or affect neuropsychological or other study outcomes.
- Current treatment with antipsychotics, anticonvulsants (other than dilantin), other antidepressants (other than trazodone, less than or equal to 50 mg per day at bedtime), benzodiazepines (other than lorazepam) or psychostimulants.
- Any condition that, in the opinion of the study physician, makes it medically inappropriate or risky for the patient to enroll in the trial.

>>NCT02360657
Inclusion Criteria:.
- Participant must have had sufficient education or work experience to exclude mental retardation based on Diagnostic and Statistical Manual of Mental Disorders 4th edition, Text Revision (DSM-IV-TR) and must be able to read and write and must have adequate hearing and visual acuity to complete the required psychometric tests.
- Participant must have a Clinical Dementia Rating Scale- Japanese version (CDR-J) score of '0' and as such rated as normal.
- Participant must have evidence of amyloid deposition as demonstrated by low Cerebrospinal Fluid (CSF) Amyloid (A)-beta 1-42 levels at Screening.
- Participant must have a body mass index between 18 and 35 kilogram per square meter, inclusive, at Screening.
- Participant must be otherwise healthy for their age group or medically stable with or without medication on the basis of physical examination, medical history, vital signs and 12-lead electrocardiogram (ECG) performed at Screening or at Baseline.
Exclusion Criteria:.
- Participant has evidence of any brain disease other than potential very early signs of Alzheimer's disease (AD) or typical age related changes or any other abnormality that could explain a possible cognitive deficit.
- Participant has been diagnosed with dementia due to AD, due to other diseases or with AD and contribution of other disorders (mixed dementia).
- Participant has evidence of familial autosomal dominant AD.
- Participant has any contra-indications for Magnetic Resonance Imaging (MRI) (for example, prostheses, implants, claustrophobia, pacemakers and others).
- Participant has a clinically significant abnormal physical- or neurological examination, vital signs or 12-lead ECG (including QTc greater than 450 millisecond for males and females, left bundle branch block, atrio-ventricular [AV] block second degree or higher, permanent pacemaker or implantable cardioverter defibrillator [ICD]) at Screening or Baseline, which in the opinion of the investigator is not appropriate and reasonable for the population under study.

>>NCT00469456
Inclusion Criteria:.
- Male and female outpatients, 50 years or older, native English speakers, meeting National Institute of Neurological and Communicative Disorders and Stroke--Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for probable AD with a Mini Mental State Examination (MMSE) score of 10 to 19 at Screening and Baseline.
Exclusion Criteria:.
- Current Diagnostic and Statistical Manual of Mental Disorders--Fourth Edition (DSM-IV) Axis I disorder other than AD.
- Previous imaging results not consistent with the diagnosis of AD.
- Modified Hachinski Ischemia Score greater than 4.
- Evidence of other neurologic disorders.
- Clinically significant systemic disease.
- A known or suspected history of alcohol or drug abuse in the past 5 years.
- Taking excluded medication.
- Previous treatment with commercial memantine.

>>NCT02547818
Inclusion Criteria:.
- 55-79 years old;.
- >= 8 years of education;.
- Study partner is available who has frequent contact with the participant (e.g. an average of 10 hours per week or more) and can accompany the participant to all clinic visits for the duration of the protocol;.
- Evidence of early AD, as defined by all of the following:.
1. Memory complaint by subject or study partner that is verified by a study partner;.
2. Objective memory impairment for age, documented by scoring below the education adjusted cutoff of the Logical Memory II subscale (Delayed Paragraph Recall) from the Wechsler Memory Scale Third Edition (the maximum score is 25):.
- <= 8 for 16 or more years of education, or.
- <= 4 for 8-15 years of education;.
- Essentially preserved general cognitive function;.
- Largely intact functional activities;.
- Not demented;.
- Cerebrospinal fluid (CSF) biomarker results consistent with early AD, including CSF A-42 levels >= 200 pg/mL and <= 600 pg/mL;.
- Clinical Dementia Rating (Global) = 0.5; Memory Box score must be at least 0.5;.
- Must be fluent in the language of the cognitive testing material being administered;.
- Stability of permitted medications for 4 weeks prior to study start; subjects receiving acetylcholinesterase inhibitors and/or memantine should be on stable dose of those medications for at least 12 weeks prior to study start with every effort to maintain stable dose for the duration of the study;.
- Visual and auditory acuity adequate for neuropsychological testing;.
- Good general health with no diseases expected to interfere with the study;.
- Must provide written informed consent for APOe4 genotype testing;.
- Must provide written informed consent for CSF sampling.
Exclusion Criteria:.
- Any significant neurological disease other than suspected incipient AD, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities;.
- Major depressive episode, as described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) within the past 6 months, which could lead to difficulty complying with the protocol;.
- History of schizophrenia or bipolar disorder (DSM-IV criteria);.
- History of alcohol or substance abuse or dependence within the past 3 years (DSM-IV criteria);.
- Currently taking medications that could lead to difficulty complying with the protocol; subjects must be on a stable dose of current medications for 4 weeks prior to study entry, with the exception of acetylcholinesterase inhibitors and/or memantine, which must be on a stable dose for at least 12 weeks prior to study entry;.
- Investigational agents are prohibited one month prior to entry and for the duration of the trial;.
- Currently taking medications known to be CYP2C9 inducers (i.e. carbamazepine and rifampicin);.
- Currently taking cromolyn or have taken cromolyn, within the past 12 months;.
- Chronic daily use of high-dose NSAID for osteoarthritis, rheumatoid arthritis or other chronic inflammatory diseases ("chronic" defined as 3200 mg/day for >2 weeks);.
- Chronic daily use of aspirin exceeding standard of care guidelines for low dose aspirin therapy for prevention of stroke and/or other recommended uses;.
- Allergy to cromolyn (also known as Intal, Nasalcrom, Opticrom, Gastrocrom, etc.);.
- Allergies to ibuprofen (Advil, Motrin, Nuprin, etc.) or aspirin;.
- Clinically significant respiratory disorders with impaired respiratory effort or difficulty taking inhaled drugs;.
- Uncontrolled chronic asthma;.
- Abnormal pulmonary function test, defined for this protocol as: FEV1/FVC < predicted value for subject AND FEV1 < 70% of predicted value, indicating moderate or severe respiratory obstruction;.
- Taking inhaled protein products on a chronic basis;.
- Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol;.
- Pregnancy or lactation for female subjects of child-bearing potential (i.e., < two years post-menopausal or not surgically sterile);.
- For sexually active male subjects, unwillingness or incapability of using appropriate contraception methods;.
- Severe renal or hepatic impairment.